News / Business
Alnylam Pharmaceuticals Inc (ALNY) Announces R&D Day Presentation March 6
Alnylam Pharmacueticals (NASDAQ:ALNY) has announced the date of the next R&D day to be held on March 6 at 9 am.
A biopharmaceutical company, Alynlam Pharmaceuticals is engaged in the development of novel therapeutics based on ribonucleic acid interference (RNAi).
The company’s primary program is currently in Phase 1 of clinical trials to treat human respiratory syncytial virus (RSV) infection. The company is also involved in creating a RNAi therapeutic to treat influenza with Novartis Pharma AG. In addition, the company is independently developing an RNAi therapeutic to treat hypercholesterolemia.
Alnylam has pre-clinical discovery programs aimed toward RNAi therapeutics development to treat a variety of diseases, such as Parkinson’s disease, Huntington’s disease, neuropathic pain, progressive multifocal leukoencephalopathy, ebola fireus invection and cystic fibrosis.
For more Conference Call related events or to post your own events, visit:
